An Economic Evaluation of Donepezil in Mild to Moderate Alzheimer’s Disease: Results of a 1-Year, Double-Blind, Randomized Trial

Wimo, Anders; Winblad, Bengt; Engedal, Knut; Soininen, Hilkka; Verhey, Frans; Waldemar, Gunhild; Wetterholm, Anna-Lena; Mastey, Vera; Haglund, Anders; Zhang, Richard; Miceli, Robert; Chin, Warren; Subbiah, Ponni

doi:10.1159/000066669

Public

An Economic Evaluation of Donepezil in Mild to Moderate Alzheimer’s Disease: Results of a 1-Year, Double-Blind, Randomized Trial

Shared by NobleBlocks on Dec 5, 2002 • 12:00 AM UTC

Authors:

Anders Wimo

Bengt Winblad

Knut Engedal

Abstract

The costs and consequences of donepezil versus placebo treatment in patients with mild to moderate Alzheimer’s disease (AD) were evaluated as part of a 1-year prospective, double-blind, randomized, multinational clinical trial. Patients received either donepezil (n = 142; 5 mg/day for 28 days follow...

Discussions